APEALEA® (paclitaxel)

Drug APEALEA® paclitaxel APEALEA Overview Apealea is a cancer medicine used to treat women with cancer of the ovary or surrounding structures (the fallopian tube that connects the ovary to the womb, or the peritoneum, the membrane that lines the abdomen). Apealea is given along with a platinum-based medicine, carboplatin, to patients whose disease responds […]

MVASI® (bevacizumab)

Drug MVASI® Bevacizumab Mvasi Overview This is a summary of the European public assessment report (EPAR) for Mvasi. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Mvasi. For practical information about using Mvasi, […]

AVASTIN® (bevacizumab)

Drug AVASTIN® bevacizumab Avastin Overview This is a summary of the European public assessment report (EPAR) for Avastin. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Avastin. For practical information about using Avastin, […]

LYNPARZA® (olaparib)

Drug LYNPARZA® olaparib Lynparza Overview Lynparza is a cancer medicine used on its own for: continuing treatment of high-grade (fast-growing) cancers of the ovaries, fallopian tubes (which connect the ovaries to the womb) and the peritoneum (membrane lining the abdomen) in: women whose cancer had come back (relapsed) after previous treatment and in whom platinum-based […]

CAELYX® (doxorubicin)

Drug CAELYX® doxorubicin  Caelyx Overview This is a summary of the European public assessment report (EPAR) for Caelyx. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Caelyx. How is Caelyx used? Caelyx should be […]

ZEJULA® (niraparib)

Drug ZEJULA® niraparib Zejula Overview This is a summary of the European public assessment report (EPAR) for Zejula. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Zejula. For practical information about using Zejula, […]